May 22, 2017
Canagliflozin - an inhibitor of subtype 2 sodium-glucose transport (SGLT-2) proteins of the gliflozin class. It is used as an anti-diabetic drug for the treatment of type 2 diabetes either as monotherapy or in combination with other medications such as metformin, sulfonylurea, and pioglitazone. SGLT-2 is responsible for at least 90% of renal glucose reabsorption and blocking this transporter causes blood glucose to be eliminated through urine. It may have positive effects on cardiometabolic health by improving adipose tissue function in patients with type 2 diabetes mellitus (T2DM). Treatment with canagliflozin cause a reduction in serum leptin and IL-6 levels as well as an increase in adiponectin and TNFa levels compared to glimepiride.
